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Abstract
Background: Alanine transaminase (ALT) and aspartate aminotransferase (AST) are referred to as liver transaminases.
Although used routinely in clinical practice for decades, their role as predictors of mortality has not been examined
until recently. We studied the predictive value of these serum transaminases in patients with ST-segment elevation
myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI).
Methods: We analyzed records of 2417 consecutive STEMI patients with no preexisting liver disease who were treated
with primary PCI at the Cardiovascular Center in the First Hospital of Jilin University. The outcomes measured were
all-cause mortality at the first month and at 2 years. The relationship between the baseline serum transaminase levels
and primary outcome was determined.
Results: We found a significant correlation between elevated liver transaminases and the Killip classification (P < 0.001
for ALT; P < 0.001 for AST), cardiac troponin I (P = 0.002 for ALT; P < 0.001 for AST), infarct-related coronary artery
(P = 0.036 for ALT; P = 0.011 for AST), and pre-thrombolysis-in-myocardial-infarction (pre-TIMI) flow (P < 0.001 for ALT
and AST). The serum level of ALT and AST were high along with the increasing of the grade of Killip classification. The
primary infarct-related coronary artery in patients with ALT ≥95th percentage was left anterior descending artery (56%),
followed by right coronary artery (36%). The OR for all-cause mortality at 2 years for participants with ALT ≥95th
percentage was 5.370 (95% CI: 2.899–9.948), 7.034 (95% CI: 3.718–13.307) after adjustment for age and gender and 1.
051 (95% CI: 0.302–3.652) after adjustment for all covariables. The OR for all-cause mortality at 2 years for participants
with AST ≥95th percentage was 5.370 (95% CI 2.899–9.948) and 5.699 (95% CI 3.030–10.718) after adjustment for age
and gender and 1.796 (95% CI: 0.588–5.481) after adjustment for all covariables. ALT (HR 1.004, 95% CI 1.001–1.006,
P = 0.010) and AST (HR 0.999, 95% CI 0.998–1.000, P = 0.030) were associated with early all-cause mortality in patients with
STEMI treated with PCI but not at 2 years post-procedure, unless for AST and ALT levels ≥95th percentage. Moreover,
short- and long-term outcomes were significantly worse when both AST and ALT levels ≥95th percentage (P < 0.001).
Conclusions: Serum transaminases ≥95th percentage were associated with a significantly increased incidence of
short- and long-term all-cause mortality.
Trial registration: Registration number: ChiCTR-EPC-16008199, 31 March 2016.
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Background
Alanine transaminase (ALT) and aspartate aminotrans-
ferase (AST) are referred to as liver transaminases. Al-
though their levels have been tested routinely in clinical
practice for decades, their role as predictors of mortality
has not been examined until recently. ALT is found pre-
dominantly in hepatocytes and is a widely used specific
serum marker of liver disease. AST is mainly derived
from the liver; although, a significant portion is derived
from other tissues, such as heart, red blood cells, and
muscle, which makes it an imperfect marker of liver
function. Recent studies have demonstrated an in-
creasing interest in investigating the role of liver trans-
aminases in independently predicting cardiac-related
morbidity and mortality [1–3].
Several prospective epidemiological studies have sug-
gested that hepatic dysfunction is common in cardiac
disease [4, 5]. If no other causes of liver injury are identi-
fied, the elevations of liver aminotransferases are associ-
ated with a higher incidence of cardiac-related mortality
[6]. However, the results from these studies have been in-
consistent and have revealed geographical variations in the
association between ALT and all-cause mortality [7–11].
Little is known about the association between hepatic dys-
function and mortality in patients with ST-segment eleva-
tion myocardial infarction (STEMI) treated with stents or
angioplasty for coronary artery stenosis. The goal of this
study was to evaluate the association between elevated liver
transaminases and all-cause mortality in patients with
STEMI undergoing primary percutaneous coronary inter-
vention (PCI) at 1-month and 2-years post-procedure.
Methods
Study population
In this study, we examined digital data from the First
Hospital of Jilin University, Cardiovascular Department,
which is located in an agricultural province of Northeast
China, populated by members of the Chinese Han ethnic
group. This prospective observational cohort study
aimed to investigate the association between ALT and
AST levels and the incidence of all-cause mortality at
1 month and 2 years following treatment. From January
1, 2013 to December 31, 2014, 6017 patients were hospi-
talized with a diagnosis of acute myocardial infarction.
Among those patients, 3692 had ST-segment elevation
myocardial infarction. From those patients, 1056 were
excluded who did not undergo angiography. Finally we
included in this study all 2636 (71.3%) consecutive
STEMI patients who underwent PCI without throm-
bolysis or conservative therapy. From this group, we
excluded 219 patients for the following reasons: insuffi-
cient AST or ALT data (n = 126), cirrhosis (n = 1), fatty
liver (n = 64), and hepatitis (n = 8). In addition, we ex-
cluded 14 patients of another ethnic group. Finally, we
excluded 16 patients because there was missing follow-
up information. The final number of patients enrolled in
this study was 2417. Their baseline demographic data,
medical history, laboratory data, and clinical data during
hospitalization were retrieved from the department’s
heart disease electronic database (Table 1). The mean
time to follow up was 2 years (30–1165 days) in the in-
cluded patients. Angiographic features, angiographic
results, and treatment characteristics are provided in
Table 2. The study protocol was approved by the ethics
review board of the First Hospital of Jilin University
(No.2016-263).
Laboratory data
Peripheral blood samples were obtained at the time of ad-
mission and the following were tested: creatinine, cardiac
troponin I (Tn I), creatine kinase MB (CKMB), K+, Na+,
and N-terminal pro-brain natriuretic peptide (NT-
proBNP). Total cholesterol (TC), triglyceride (TG), high-
density lipoprotein cholesterol (HDL-C), glucose, ALT,
AST, alkaline phosphatase (ALP), -glutamyl trans-
peptidase (GGT), and low-density lipoprotein cholesterol
(LDL-C) were measured after 12-hours fasting following
admission. All blood samples obtained at the time of ad-
mission were analyzed in the certified laboratory depart-
ment of First Hospital of Jilin University. ALT and AST
were determined using ultraviolet-lactate dehydrogenase
method and ultraviolet-malic acid dehydrogenase method
according to the manufacturers’ instructions (Kehua Bio-
Engineering, China). According to local recommended
guidelines, an abnormal ALT level was defined as a serum
concentration >50 U/L for men and >40 U/L for women;
an abnormal AST level was defined as a serum concentra-
tion >40 U/L for men and >35 U/L for women.
Protocol and definition
STEMI was diagnosed in accordance with the European
Society of Cardiology/American College of Cardiology
consensus document, using at least two separate measure-
ments for the following parameters: a past history of chest
pain, diagnostic electrocardiographic changes, and serial
elevation of serum cardiac biomarkers [12]. The Killip
classification is a system used in individuals with an acute
myocardial infarction, taking physical examination and
the development of heart failure to predict and stratify
their risk [13]. It was determined as follows: Killip class I,
no clinical signs of heart failure; Killip class II, rales or
crackles in the lungs, an S3, and elevated jugular venous
pressure; Killip class III, frank acute pulmonary edema;
and Killip class IV, cardiogenic shock or hypotension and
evidence of peripheral vasoconstriction [13].
All patients enrolled were pre-medicated with either 1)
300 mg aspirin or 2) 600 mg clopidogrel orally and un-
fractionated heparin (1000 IU/L intravenous injection).
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Coronary angiography was performed through the fem-
oral or radial artery using standard techniques to evaluate
coronary artery lesions. Multivessel coronary artery dis-
ease was defined as significant stenosis of two or more
major coronary arteries, stenosis of ≥50% of the diameter
in the left main or proximal segment of the left anterior
descending artery (LAD), and stenosis of ≥70% of the
diameter in two of these three vessels: left coronary artery,
right coronary artery (RCA), and left circumflex coronary
artery (LCX). An artery was considered infarct-related if
one of the following criteria was present: definite or sus-
pected thrombus, a ruptured or ulcerated plaque, the
presence of thrombolysis-in-myocardial-infarction (TIMI)
flow grade ≤2, or stenosis ≥70% of the diameter. The cor-
onary artery flow was assessed using TIMI flow grades
[14]. The strategy for multivessel arteries disease in our
center was infarct-related artery only according to current
guideline recommendations which encourage culprit-only
PCI in patients with STEMI and multivessel disease
(excluding cardiogenic shock) [15, 16].
Follow-up
To monitor for all-cause mortality following discharge,
the clinical course of the patients was monitored by tele-
phone until death or April 1, 2016, whichever occurred
first. In the case of patients who were lost to follow-up,
we reviewed all medical records and contacted the
patients’ families. The endpoint of the present study
was defined in separate analyses of all-cause mortality
at 1-month and at 2-years post-procedure. Two inde-
pendent observers performed statistical analysis.
Table 1 Baseline characteristics of participants (n = 2417)
Characteristic N (%) or mean ± SD
Demographic data
Age (year) 59.5 ± 11.1
Male, n (%) 1748 (72)
Living in the city 11,148 (48)
Hospital days 7.2 ± 3.8
Medical history (n)
Dyslipidemia 931 (38)
Diabetes mellitus 545 (23)
Hypertension 1088 (45)
Myocardial disease 160 (7)
Previous myocardial infarction 24 (1)
Arrhythmias 492 (20)
Previous stroke 75 (3)
Malignancies 6 (0.2)
Peripheral vascular disease 24 (1)
COPD 30 (1)





Cardiogenic shock 101 (4)
Noncardiogenic shock 2316 (96)
Laboratory data
K+ (mmol/L) 3.9 ± 0.5
Creatinine (mmol/L) 75.3 ± 29.8
Na+ (mmol/L) 139.4 ± 4.1
Total cholesterol (mmol/L) 4.5 ± 1.0
HDL-C (mmol/L) 1.1 ± 0.3
LDL-C (mmol/L) 2.8 ± 0.9
Triglycerides (mmol/L) 1.7 ± 1.2
Glucose (mmol/L) 7.1 ± 3.1
ALT (unit/L) 55.5 ± 108.3
AST (unit/L) 165.3 ± 283.1
ALP (unit/L) 72.4 ± 24.4
GGT (unit/L) 47.4 ± 69.4
Cardiac troponin I (ng/mL) 20.9 ± 60.9
Creatine kinase MB (ng/ml) 38.3 ± 75.9
NT-proBNP (pg/mL) 1829.9 ± 6019.6
SD standard deviation, COPD chronic obstructive pulmonary disease,
ECG electrocardiographic, HDL-C high-density lipoprotein cholesterol,
LDL-C low-density lipoprotein cholesterol, ALT alanine aminotransferase,
AST aspartate aminotransferase, ALP Alkaline phosphatase, GGT ɤ-glutamyl
transpeptidase, NT-proBNP N-terminal pro-brain natriuretic peptide
Table 2 Angiographic features, angioplasty results, and







TIMI-0 flow 475 (20)
≥ TIMI −1 flow 1,942 (80)
Multivessel disease (≥2 vessels) 1145 (47)
Method of reperfusion, n (%)
Balloon 282 (12)
Stent implantation 2135 (88)
All-cause mortality
1-month death 59 (2)
24-month death 128 (5)
RCA right coronary artery, LAD left anterior descending, LCX left circumflex
coronary artery, TIMI thrombolysis in myocardial infarction
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Statistical analysis
After testing for normality by the Kolmogorov-Smirnov
test, the data were presented as mean ± standard devi-
ation (SD) or median [interquartile range]. Separate ana-
lyses were conducted for ALT and AST. Serum ALT and
AST levels were categorized into percentiles separately
(<25th, 25th to <50th, 50th to <75th, 75th to <95th,
and ≥95th percentages). Liver enzyme levels <25th
percentage were used as a reference. Logistic regression
was performed to evaluate the power of percentiles for
each liver enzyme with all-cause mortality. AUC curves
were constructed to further illuminate the best cut-off
values for ALT and AST for predicting the all-cause mor-
tality. Multiple linear regression was used in order to test
the association of the liver enzymes and other previously
identified prognostic factors in STEMI with the measured
outcomes. Survival curves were generated by the Kaplan–
Meier method, and survival among groups was compared
using the Log Rank test. To evaluate the independent con-
tribution of the baseline clinical characteristics, medical
history, and laboratory data on the occurrence of major
events, two consecutive models of Cox multiple regression
analysis were performed with forward stepwise selection
to determine predictors for all-cause mortality at 1 month
and 2 years separately. In the first model, the baseline
clinical characteristics and laboratory data were included.
Only those clinical and laboratory variables found to be
independent in the first model were included in the
second model. For all analyses, a two-sided P < 0.05 was
considered statistically significant. All analyses were




The baseline data of the participants included demo-
graphic characteristics, medical history, laboratory data,
culprit vessel, and PCI procedure. The median age of the
2417 patients was 60 years [interquartile range: 52–67]
with 72% male patients. Using the definitions of abnor-
mal liver enzyme levels defined previously, 38.9% of the
study population had elevated ALT and 71.9% of the
study population had elevated AST (Table 1). During the
median 2 years (ranging from 30 to 1165 days, median
775 days) of follow up, the cumulative data for all-cause
mortality was 2% (59 deaths) at the first month and 5%
(122 deaths) at 2 years (Table 2).
Risk factors and elevated liver enzymes
We found some differences in the associations between
known risk factors and elevated liver enzymes between
ALT and AST. Variables found to be independent in the
first regression model and further analyzed included age,
gender, living in rural regions, hospital days, medical
history, Killip classification, infarct-related coronary
artery, Tn I, pre-TIMI, and multivessel disease. In
multivariate regression analysis, elevated ALT and AST
were both related to Killip classification (P < 0.001 for
ALT; P < 0.001 for AST), Tn I (P = 0.002 for ALT; P < 0.001
for AST), infarct-related coronary artery (P = 0.036 for
ALT; P = 0.011 for AST), and pre-TIMI flow (P < 0.001 for
ALT and AST). ALT was also related to age (P = 0.002) and
dyslipidemia (P = 0.048) (Table 3). The serum level of ALT
and AST were high along with the increasing of the grade
of Killip classification (Fig. 1). The primary infarct-related
coronary artery in patients with ALT ≥95th percentage was
LAD (56%), followed by RCA (36%).
At cox proportional hazards regression, ALT (hazard ra-
tio [HR] 1.004, 95% confidence interval [CI] 1.001–1.007,
P = 0.010) and AST (HR 0.999, 95% CI 0.098–1.000,
P = 0.030) were associated with of all-cause mortality
at 1 month but not at 2 years after adjustment for
potential confounders (Additional file 1: Table S1 and
Table S2).
Transaminases stratification and clinical outcome
Values for the percentages of ALT and AST in males and
females in the study population are shown (Additional
file 1: Table S3). The odds ratio (OR) for all-cause
mortality at 2 years for participants with ALT ≥95th
percentage was 5.370 (95% CI: 2.899–9.948), 7.034 (95%
CI: 3.718–13.307) after adjustment for age and gender
and 1.051 (95% CI: 0.302–3.652) after adjustment for all
covariables. The OR for all-cause mortality at 2 years for
participants with AST ≥95th percentage was 5.370 (95%
CI 2.899–9.948), 5.699 (95% CI 3.030–10.718) after
adjustment for age and gender and 1.796 (95% CI:
0.588–5.481) after adjustment for all covariables
(Table 4). For predicting outcomes, we constructed the
receiver operating characteristic area under the curve
(ROC-AUC) to value the best cut-off of ALT and AST.
Using a cut-off level of 63.65 IU/L, ALT predicted
1 month mortality with a sensitivity of 75.19% and speci-
ficity of 50.85% (ROC-AUC: 0.635, 95% CI: 0.552 to
0.719, P < 0.001) and 2 year mortality with a sensitivity
of 75.56% and specificity of 44.26% (ROC-AUC: 0.604,
95% CI: 0.546 to 0.662, P < 0.001). Using a cut-off level
of 310.5 IU/L, AST predicted 1 month mortality with a
sensitivity of 84.56% and specificity of 42.37% (ROC-AUC:
0.665, 95% CI: 0.587 to 0.743, P < 0.001) and 2 year mor-
tality with a sensitivity of 84.75% and specificity of 31.97%
(ROC-AUC: 0.577, 95% CI: 0.520 to 0.634, P = 0.004).
The 2 year all-cause mortality was significantly high
along with an increasing level of ALT and AST (Table 4).
Kaplan-Meier curves were constructed to explore the
additive prognostic value of combinations of ALT and
AST levels. We divided the study patients into four
groups by ≥95th percentage of ALT and AST or not.
Gao et al. BMC Cardiovascular Disorders  (2017) 17:43 Page 4 of 8
The all-cause mortality at 1 month and 2 years were
significantly increased in patients with both AST and
ALT levels ≥95th percentage (P < 0.001) (Fig. 2).
Discussion
Liver function tests usually comprise ALT, AST, ALP,
GGT, other nonenzymatic proteins (e.g., albumin), and
heme metabolites, such as bilirubin. Among these
markers, AST and ALT are often elevated in patients
with STEMI [17]. Serum ALT is predominantly found in
the liver. AST is mainly derived from liver and, hence,
also considered as a marker of liver function; however, a
significant portion of AST is derived from the heart and
other tissues. Nevertheless, it remains unclear whether
ALT or AST provide any long- or short-term independ-
ent prognostic value in STEMI patients who underwent
PCI and whether ALT and AST levels are associated
with any other risk factors.
To our knowledge, this is the first prospective study
evaluating the association between ALT and AST and
short- and long-term all-cause mortality in STEMI
patients who underwent PCI. We demonstrated in the
Chinese Han ethnic group that AST and ALT levels on
admission were significant correlated with Killip classifi-
cation, pre-TIMI flow, infarct-related coronary artery,
and cardiac troponin I. Serum transaminases ≥95th
percentage were associated with a significantly increased
incidence of short- and long-term all-cause mortality.
Recent studies investigating the relationship between
ALT and AST with mortality have yielded conflicting
results. A large national population-based cohort study
conducted in the United States showed a lack of associ-
ation between overall or cardiovascular-disease (CVD)
mortality with ALT [18]. However, a similar study of a
population-based cohort of Caucasian persons aged
55 years or older found AST and ALT are associated
with all-cause mortality [19]. Furthermore, a recent
meta-analysis study with aggregate data on over 9.24
million participants and 242,953 instances of all-cause
mortality found a comparatively moderate association of
AST with all-cause mortality and geographical variations
in the association of ALT with all-cause mortality risk in
Table 3 Association between liver enzymes and covariables in univariate analyses
Variable CC for ALT (SE) P value CC for AST (SE) P value
Age (year) 30.456 (3.275) 0.002 −0.467 (0.546) 0.392
Male, n (%) 4.316 (5.199) 0.407 14.206 (13.344) 0.287
Living in the city −5.163 (4.548) 0.256 −17.423 (11.674) 0.136
Hospital days 0.164 (0.602) 0.785 −2.807 (1.545) 0..069
Dyslipidemia (n) −9.094 (4.604) 0.048 −20.057 (11.818) 0.090
Diabetes mellitus (n) −3.187 (5.399) 0.555 −11.918 (13.859) 0.390
Hypertension (n) 1.631 (4.536) 0.719 3.295 (11.642) 0.777
Myocardial disease (n) −17.047 (9.239) 0.065 −38.681 (23.715) 0.103
Killip classification 30.456 (3.275) <0.001 83.942 (8.406) <0.001
Infarct-related coronary artery 8.766 (4.176) 0.036 27.303 (10.718) 0.011
cardiac troponin I (ng/mL) 0.116 (0.037) 0.002 0.809 (0.094) <0.001
Pre-TMI flow −29.730 (5.587) <0.001 −69.304 (14.339) <0.001
Multivessel disease (≥2 vessels) 7.055 (4.539) 0.120 17.559 (11.650) 0.132
CC correlation coefficient, ALT alanine aminotransferase, SE standard error, AST aspartate aminotransferase, NT-proBNP N-terminal pro-brain natriuretic peptide
Fig. 1 ALT (a) and AST (b) values stratified according to Killip classification. The horizontal line shows the median value. The box showed the
interquartile range. The vertical line shows the 10th–90th percentage
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general populations [7]. Interestingly, other studies have
found elevation of common markers, including ALT and
AST, in patients with heart failure and CVD with liver
injury resulting from ischemia or congestion [20–23].
These results further confirm the association between
ALT/AST and mortality risk. Considering that liver en-
zymes are routine parameters of liver function assessed
in STEMI patients before PCI, we investigated the
association between ALT/AST and all-cause mortality in
the Chinese Han ethnic group.
Notably, increased ALT levels are found in STEMI pa-
tients with acute liver injury [24–26]. Cardiac disorders
contribute to the liver injury [2, 4, 27, 28]. We excluded
patients with chronic hepatitis to exclude liver injury
derived from hepatic disorders. The infarct-related artery
only strategy for patients with multivessel arteries
disease presenting with STEMI in our center minimize
potential impact of different strategies of complete vs.
culprit-only revascularization [29]. The primary infarct-
related coronary artery in patients with ALT ≥ 95th per-
centage was LAD. Our findings support LAD occlusion
as the factor most closely associated with left ventricular
ejection fraction and with measures of left ventricular
regional hypofunction, especially caused by proximal
LAD [30, 31].
The liver has high metabolic activity and perfusion
rate, and acute circulatory changes, such as cardiogenic
shock resulting from an acute myocardial infarction,
directly influence hepatic blood flow [32–34]. Every
10 mmHg drop in arterial pressure decreases the hepatic
blood flow by approximately 10% [33, 35]. Circulatory
failure triggers compensatory mechanisms in the liver by
increasing oxygen extraction from the blood up to 95%,
which results in hepatocellular dysfunction and elevation
of AST/ALT [36]. The assessment for the presence and
severity of circulatory failure were assessed by the Killip
classification through physical examination, which
showed the serum level of ALT and AST were high
along with the increasing of the grade of Killip classifica-
tion. Because hypoxic injury to the liver is a reversible
subclinical condition accounting for over 50% of
dramatic serum aminotransferase activity identified in
hospital admissions [37], our results demonstrating the
Table 4 Association of liver enzymes with long-term all-cause mortality
Association of ALT with all-cause mortality
Category ALT (unit/L) Crude univariate model Adjusted for age and sex Adjusted for all covariables
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
ALT (1)a ≤23 1 (ref) <0.001 1 (ref) <0.001 1 (ref) <0.001
ALT (2) >23 to ≤39 0.957 0.534–1.714 1.126 0.624–2.030 1.358 0.650–2.834
ALT (3) >39 to ≤64 0.914 0.506–1.648 1.124 0.618–2.041 1.413 0.658–3.036
ALT (4) >64 to ≤125 1.654 0.957–2.858 2.144 1.226–3.751 1.650 0.732–3.719
ALT (5) ≥125 5.370 2.899–9.948 7.034 3.718–13.307 1.051 0.302–3.652
Association of AST with all-cause mortality
Category AST (unit/L) Crude univariate model Adjusted for age and sex Adjusted for all covariables
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
AST (1)a ≤32 1 (ref) <0.001 1 (ref) <0.001 1 (ref) <0.001
AST (2) >32 to ≤93 1.442 0.844–2.462 1.432 0.834–2.459 1.379 0.700–2.717
AST (3) >93 to ≤233 0.785 0.425–1.448 0.744 0.401–1.382 0.786 0.361–1.715
AST (4) >233 to ≤492 1.206 0.672–2.164 1.152 0.639–2.080 0.989 0.439–2.225
AST (5) ≥492 5.370 2.899–9.948 5.699 3.030–10.718 1.796 0.588–5.481
HR hazard ratio, CI confidence interval, ALT alanine aminotransferase, AST aspartate aminotransferase
aPercentiles are shown in categories: (1) ≤25th percentage; (2) 25th - < 50th percentage; (3) 50th- < 75th percentage; (4) 75th- < 95th percentage; (5) ≥95th percentage
Fig. 2 Kaplan-Meier analysis. All-cause mortality according to
combinations generated by having low or high values for ALT and
AST. ALT and AST were defined low if under 95th percentage, high if
above 95th percentage. ALT 95th percentage value = 125 unit/L, AST
95th percentage value = 492 unit/L
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predictive value of ALT and AST for short-term, but not
long-term, all-cause mortality were not surprising. The
influences of genetics on the ethnic and environmental
factors, the dosage of prescription drugs, adherence to
therapy and cardiac rehabilitation all had important roles
on the long-term overall cardiovascular risk. Unless for
ALT and AST levels ≥95th percentage, the all-cause
mortality at 1 month and 2 years post-procedure both
significantly increased.
Study limitations
This study had several limitations. This was an observa-
tional study based on data from a single center and the
population belonging to a single ethnic group which lo-
cated in an agricultural province of Northeast China
with 52% of participants living in the countryside. The
crude death rate of coronary heart disease is significantly
different form urban citizens and rural residents in
China [38]. The proportion of rural population may
influence the result and the data may not reflect the
general population of STEMI patients; however, com-
pared to a multicenter study, this study design could be
an advantage. The patients’ data were imputed electron-
ically by a relatively constant group of attending physi-
cians. The severity and location of coronary lesions were
based on visual assessments by the same operators.
Ticagrelor was not available during the study period in
our center which avoided different P2Y12 inhibitors
affecting AST and ALT levels. The overall strategic man-
agement of patients, including PCI technique and device
used during the procedure, were more homogeneous
than would be in a multi-centered study. Second, we
performed only a single measurement of ALT and AST
for most patients admitted to our center. We tried to
exclude patients with conditions potentially associated
with liver cell damage, and we also excluded 5% of
patients who did not have complete evaluation of liver
enzymes at admission. Those limitations are balanced by
our continuous admission and, in particular, by the
avoidance of ascertainment bias that occurs in clinical
studies of selected patients. Third, the results of our
multivariate analysis may be biased due to the potential
impact of important factors that are not available in our
database. Fourth, validation of the cause of death was re-
ported only in a portion of our cohort. Due to culture
and social reasons, some patients’ families did not know
the exact cause of death.
Conclusions
In summary, to our knowledge, this is the first study to
investigate the value of serum transaminases in patients
with STEMI treated with primary PCI. Elevated transami-
nases significant correlated with Killip classification, pre-
TIMI flow, infarct-related coronary artery, and cardiac
troponin I. Moreover, the all-cause mortality at short- and
long-term post-procedure was significantly increased in
patients with levels of AST and ALT ≥95th percentage.
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